Brief: Transgene Updates On Phase II Clinical Trial Of TG4001 + Avelumab Versus Avelumab Alone

Transgene SA

24/06/2021 16:52

June 24 (Reuters) - Transgene SA  TRNG.PA :
    * FIRST PATIENT ENROLLED IN EXPANDED PHASE II CLINICAL TRIAL OF TG4001 +
AVELUMAB
VERSUS AVELUMAB ALONE IN PATIENTS WITH HPV16-POSITIVE ANOGENITAL CANCERS
    * TRANSGENE EXPECTS TO COMMUNICATE INTERIM ANALYSIS DATA AROUND END OF 2022
    * PHASE II TRIAL AIMS TO SHOW THE SUPERIORITY OF TG4001 + AVELUMAB OVER
AVELUMAB
MONOTHERAPY

Source text for Eikon:  ID:nBwDS2YKa 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))